clostridium difficile associated gastroenteritis

clostridium difficile associated gastroenteritis:
Clostridium difficile infection is responsible for approximately 3 million cases of diarrhea and colitis annually in the United States. The mortality rate is 1 to 2.5 percent. Early diagnosis and prompt aggressive treatment are critical in managing C. difficile–associated diarrhea. Major predisposing factors for symptomatic C. difficile colitis include antibiotic therapy; advanced age; multiple, severe underlying diseases; and a faulty immune response to C. difficile toxins. The most common confirmatory study is an enzyme immunoassay for C. difficile toxins A and B. The test is easy to perform, and results are available in two to four hours. Specificity of the assay is high (93 to 100 percent), but sensitivity ranges from 63 to 99 percent. In severe cases, flexible sigmoidoscopy can provide an immediate diagnosis. Treatment of C. difficile–associated diarrhea includes discontinuation of the precipitating antibiotic (if possible) and the administration of metronidazole or vancomycin. Preventive measures include the judicious use of antibiotics, thorough hand washing between patient contacts, use of precautions when handling an infected patient or items in the patient’s immediate environment, proper disinfection of objects, education of staff members, and isolation of the patient.

Guidelines for the diagnosis and treatment of Clostridioides difficile infection have recently been updated. Risk factors include recent exposure to health care facilities or antibiotics, especially clindamycin. C. difficile infection is characterized by a wide range of symptoms, from mild or moderate diarrhea to severe disease with pseudomembranous colitis, colonic ileus, toxic megacolon, sepsis, or death. C. difficile infection should be considered in patients who are not taking laxatives and have three or more episodes of unexplained, unformed stools in 24 hours. Testing in these patients should start with enzyme immunoassays for glutamate dehydrogenase and toxins A and B or nucleic acid amplification testing. In children older than 12 months, testing is recommended only for those with prolonged diarrhea and risk factors. Treatment depends on whether the episode is an initial vs. recurrent infection and on the severity of the infection based on white blood cell count, serum creatinine level, and other clinical signs and symptoms. For an initial episode of nonsevere C. difficile infection, oral vancomycin or oral fidaxomicin is recommended. Metronidazole is no longer recommended as first-line therapy for adults. Fecal microbiota transplantation is a reasonable treatment option with high cure rates in patients who have had multiple recurrent episodes and have received appropriate antibiotic therapy for at least three of the episodes. Good antibiotic stewardship is a key strategy to decrease rates of C. difficile infection. In routine or endemic settings, hands should be cleaned with either soap and water or an alcohol-based product, but during outbreaks soap and water is superior. The Infectious Diseases Society of America does not recommend the use of probiotics for prevention of C. difficile infection.




TABLE 3

Treatment of Clostridium difficile Colitis

DRUGDOSAGEMODE OF ADMINISTRATIONEFFICACYSIDE EFFECTSPRICE*ADVANTAGES AND DISADVANTAGES
Metronidazole (Flagyl)
500 mg orally every six to eight hours for 10 to 14 daysAlternatives: 250 mg every six hours for 10 to 14 days and 500 mg IV every eight hours for 10 to 14 days
Oral and IV
> 90%
Nausea, vomitingMetallic tastePotentiation of warfarin (Coumadin)Disulfiram-like reaction
$256 (36 to 40): 500 mg orally every six hours for 14 days$678 (103 to 644): 500 mg IV every eight hours for 14 days
Effective by IV administrationLess expensive than vancomycinMore side effects than vancomycin
Vancomycin (Vancocin)
125 to 500 mg orally every six hours for 10 to 14 days
Oral only†Nasogastric tubeRetention enema
> 90%
Minimal; can include unpleasant taste, mouth irritation, nausea or vomiting; rarely, rash
$1,724: 500 mg orally every six hours for 14 days
Safe for use in pregnant womenHigh costUse may lead to resistance
Vancomycin retention enemas
Uncertain
Variable

IV = intravenous.
*—Estimated cost to the pharmacist based on average wholesale prices in Red book. Montvale, N.J.: Medical Economics Data, 2004. Cost to the patient will be higher, depending on prescription filling fee.
†—Vancomycin is not secreted into the bowel; therefore, IV administration is not effective.
Information from references 13, and 19 through 21.
source--aafp

Comments

Popular posts from this blog

WHEN TO START INSULIN IN DIABETICS AND HOW TO ADJUST?